MedTrace Logo

Suzetrigine-enhanced MultimOdal Opioid-sparing THerapy in Cardiac and Bariatric SURGery

NCT07539623 · Status: RECRUITING · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 235

Last updated 2026-05-14

No results posted yet for this study

Summary

This is prospective, randomized study. The purpose of this study is to evaluate whether the addition of Suzetrigine to well established multimodal pain regimen for participants undergoing bariatric patients undergoing weight-loss surgery and cardiac patients undergoing sternotomy will reduce post-operative opioid consumption and pain scores.

Conditions

  • Bariatric Surgery
  • Cardiac Surgery With Sternotomy
  • Post-operative Pain

Interventions

DRUG

Suzetrigine

Suzetrigine is a new pain medication that works by blocking a specific sodium channel (NAV 1.8) in the peripheral nerves and preventing pain signals from reaching the spinal cord and brain.

DRUG

Placebo

Matching placebo

Sponsors & Collaborators

Principal Investigators

  • Himani Bhatt, DO · Icahn School of Medicine at Mount Sinai

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
TRIPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
85 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2026-05-01
Primary Completion
2026-12-22
Completion
2026-12-22
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07539623 on ClinicalTrials.gov